UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period______ from to______
Commission File No. 001-41351
DENALI CAPITAL ACQUISITION CORP.
(Exact name of registrant as specified in its charter)
Cayman Islands | | 98-1659463 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
| | |
437 Madison Avenue, 27th
Floor
New York, New York 10022
(Address of Principal Executive Offices, including zip code)
(646) 978-5180
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Units, each consisting of one Class A ordinary share and one redeemable warrant | | DECAU | | The Nasdaq Stock Market LLC |
Class A ordinary shares, par value $0.0001 per share | | DECA | | The Nasdaq Stock Market LLC |
Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share | | DECAW | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (v232.405 of
this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes
☒ No ☐
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging growth company | ☒ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☒ No ☐
As of August 15, 2023, there were 8,760,000 Class
A ordinary shares, $0.0001 par value per share, and 2,062,500 Class B ordinary shares, $0.0001 par value per share, issued and outstanding.
DENALI CAPITAL ACQUISITION CORP.
FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2023
TABLE OF CONTENTS
This report, including, without
limitation, statements under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations,”
includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Our forward-looking statements include, but are not limited to, statements regarding our or our management
team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including with respect to our recently announced
proposed business combination with Longevity (as defined below). In addition, any statements that refer to projections, forecasts or
other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The
words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,”
“project,” “should,” “would” and similar expressions may identify forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Quarterly Report
on Form 10-Q may include, for example, statements about:
| ● | our
ability to select an appropriate target business or businesses; |
| ● | our
ability to complete our initial business combination, including our recently announced proposed business combination with Longevity Biomedical,
Inc. (“Longevity”); |
| ● | our
expectations around the performance of the prospective target business or businesses; |
| ● | our
success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
| ● | our
officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in
approving our initial business combination; |
| ● | our
potential ability to obtain additional financing to complete our initial business combination; |
| ● | our
pool of prospective target businesses; |
| ● | our
ability to consummate an initial business combination due to the uncertainty resulting from the COVID-19 pandemic, the ongoing military
action with the country of Ukraine commenced by the Russian Federation and Belarus in February 2022, adverse changes in general economic
industry and competitive conditions, or adverse changes in government regulation or prevailing market interest rates; |
| ● | the
ability of our officers and directors to generate a number of potential business combination opportunities; |
| ● | our
public securities’ potential liquidity and trading; |
| ● | the
lack of a market for our securities; |
| ● | the
use of proceeds not held in the trust account or available to us from interest income on the trust account balance; |
| ● | the
trust account not being subject to claims of third parties; or |
| ● | our
financial performance following our initial public offering. |
The
forward-looking statements contained in this Quarterly Report on Form 10-Q are based on our current expectations and beliefs concerning
future developments and their potential effects on us. There can be no assurance that future developments affecting us will be
those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our
control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied
by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the
heading “Risk Factors,” elsewhere in this Quarterly Report on Form 10-Q and in our other filings with the Securities and
Exchange Commission (the “SEC”), including in our Annual Report on Form 10-K filed on March 17, 2023 and in our preliminary
prospectus/proxy statement included in a Registration Statement on Form S-4 filed with the SEC (by Denali SPAC Holdco, Inc.) on March
29, 2023, as amended by Amendments Nos. 1 and 2 thereto, filed with the SEC on May 31, 2023 and July 13, 2023, respectively, relating
to our proposed business combination with Longevity (the “Longevity Disclosure Statement”). Should one or more of these risks
or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
PArt
I. FINANCIAL INFORMATION
ITem
1. CONSOLIDATED FINANCIAL STATEMENTS
DENALI CAPITAL ACQUISITION CORP.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF JUNE 30, 2023
| |
June 30, 2023 | | |
December 31, 2022 | |
| |
(Unaudited) | | |
| |
ASSETS | |
| | |
| |
Current Assets: | |
| | |
| |
Cash | |
$ | 9,125 | | |
$ | 819,747 | |
Prepaid expenses | |
| 45,325 | | |
| 88,089 | |
Total Current Assets | |
| 54,450 | | |
| 907,836 | |
Investments held in Trust
Account | |
| 88,135,105 | | |
| 85,371,600 | |
Total Assets | |
$ | 88,189,555 | | |
$ | 86,279,436 | |
| |
| | | |
| | |
LIABILITIES, TEMPORARY EQUITY AND SHAREHOLDERS’ DEFICIT | |
| | | |
| | |
Current Liabilities: | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 3,336,204 | | |
$ | 1,291,641 | |
Accrued interest expense – related party | |
| 4,449 | | |
| - | |
Promissory note – related party | |
| 412,500 | | |
| - | |
Total Current Liabilities | |
| 3,753,153 | | |
| 1,291,641 | |
Deferred underwriter compensation | |
| 2,887,500 | | |
| 2,887,500 | |
Total Liabilities | |
| 6,640,653 | | |
| 4,179,141 | |
| |
| | | |
| | |
Commitments and contingencies | |
| | | |
| | |
| |
| | | |
| | |
Class A ordinary shares subject to possible redemption; 8,250,000 shares at redemption value of $10.68 and $10.35 per share as of June 30, 2023, and December 31, 2022, respectively | |
| 88,135,105 | | |
| 85,371,600 | |
| |
| | | |
| | |
Shareholders’ Deficit: | |
| | | |
| | |
Preference shares $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding | |
| — | | |
| — | |
Class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 510,000 shares issued and outstanding (excluding 8,250,000 shares subject to possible redemption) | |
| 51 | | |
| 51 | |
Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 2,062,500 shares issued and outstanding | |
| 206 | | |
| 206 | |
Additional paid-in capital | |
| — | | |
| — | |
Accumulated deficit | |
| (6,586,460 | ) | |
| (3,271,562 | ) |
Total Shareholders’ Deficit | |
| (6,586,203 | ) | |
| (3,271,305 | ) |
Total Liabilities, Temporary Equity and Shareholders’ Deficit | |
$ | 88,189,555 | | |
$ | 86,279,436 | |
The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.
DENALI CAPITAL
ACQUISITION CORP.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND FOR THE PERIOD FROM JANUARY 5, 2022 (INCEPTION)
THROUGH JUNE 30, 2022
| |
Three Months
Ended June 30, 2023 | | |
Three Months
Ended June 30, 2022 | | |
Six Months
Ended June 30, 2023 | | |
From
January 5,
2022 (Inception) Through
June 30,
2022 | |
Formation and operating costs | |
$ | 563,701 | | |
$ | 145,678 | | |
$ | 2,485,449 | | |
$ | 157,021 | |
Other expense/(income) | |
| | | |
| | | |
| | | |
| | |
Interest expense – related party | |
| 4,449 | | |
| - | | |
| 4,449 | | |
| - | |
Income on Trust Account | |
| (1,025,859 | ) | |
| (114,831 | ) | |
| (1,938,505 | ) | |
| (114,831 | ) |
Net income/(loss) | |
$ | 457,709 | | |
$ | (30,847 | ) | |
$ | (551,393 | ) | |
$ | (42,190 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average shares outstanding of redeemable ordinary shares | |
| 8,250,000 | | |
| 7,343,407 | | |
| 8,250,000 | | |
| 3,775,424 | |
Basic and diluted net income per share, redeemable ordinary shares | |
$ | 0.10 | | |
$ | 0.55 | | |
$ | 0.03 | | |
$ | 1.41 | |
Weighted average shares outstanding of non-redeemable ordinary shares | |
| 2,572,500 | | |
| 2,495,852 | | |
| 2,572,500 | | |
| 1,886,992 | |
Basic and diluted net loss per share, non-redeemable ordinary shares | |
$ | (0.13 | ) | |
$ | (1.64 | ) | |
$ | (0.31 | ) | |
$ | (2.85 | ) |
The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.
DENALI CAPITAL ACQUISITION
CORP.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN
SHAREHOLDERS’ DEFICIT
FOR THE THREE AND SIX MONTHS
ENDED JUNE 30, 2023
| |
Ordinary Shares | | |
Additional | | |
| | |
| |
| |
Class A | | |
Class B | | |
Paid-In | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
Balance as of December 31, 2022 | |
| 510,000 | | |
$ | 51 | | |
| 2,062,500 | | |
$ | 206 | | |
$ | — | | |
$ | (3,271,562 | ) | |
$ | (3,271,305 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (1,009,102 | ) | |
| (1,009,102 | ) |
Subsequent measurement of Class A ordinary shares subject to possible redemption (income earned on Trust Account) | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (912,646 | ) | |
| (912,646 | ) |
Balance as of March 31, 2023 | |
| 510,000 | | |
| 51 | | |
| 2,062,500 | | |
| 206 | | |
| — | | |
| (5,193,310 | ) | |
| (5,193,053 | ) |
Net income | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 457,709 | | |
| 457,709 | |
Subsequent measurement of Class A ordinary shares subject
to possible redemption (income earned on Trust Account and extension deposit) | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (1,850,859 | ) | |
| (1,850,859 | ) |
Balance as of June 30, 2023 | |
| 510,000 | | |
$ | 51 | | |
| 2,062,500 | | |
$ | 206 | | |
$ | — | | |
$ | (6,586,460 | ) | |
$ | (6,586,203 | ) |
FOR THE PERIOD FROM JANUARY 5, 2022 (INCEPTION) THROUGH JUNE 30,
2022
| |
Ordinary Shares | | |
Additional | | |
| | |
| |
| |
Class A | | |
Class B | | |
Paid-In | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
Balance as of January 5, 2022 (inception) | |
| — | | |
$ | — | | |
| — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | |
Issuance of Class B ordinary shares to Sponsor | |
| — | | |
| — | | |
| 2,156,250 | | |
| 216 | | |
| 24,784 | | |
| — | | |
| 25,000 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (11,343 | ) | |
| (11,343 | ) |
Balance as of March 31, 2022 | |
| — | | |
| — | | |
| 2,156,250 | | |
| 216 | | |
| 24,784 | | |
| (11,343 | ) | |
| 13,657 | |
Proceeds from sale of Public Units | |
| 7,500,000 | | |
| 750 | | |
| — | | |
| — | | |
| 74,999,250 | | |
| — | | |
| 75,000,000 | |
Proceeds from sale of Public Units-overallotment | |
| 750,000 | | |
| 75 | | |
| — | | |
| — | | |
| 7,499,925 | | |
| — | | |
| 7,500,000 | |
Proceeds from sale of Private Placement Units | |
| 480,000 | | |
| 48 | | |
| — | | |
| — | | |
| 4,799,952 | | |
| — | | |
| 4,800,000 | |
Proceeds from sale of Private Placement Units-overallotment | |
| 30,000 | | |
| 3 | | |
| — | | |
| — | | |
| 299,997 | | |
| — | | |
| 300,000 | |
Deferred underwriting fees payable at 3.5% of gross proceeds | |
| — | | |
| — | | |
| — | | |
| — | | |
| (2,887,500 | ) | |
| — | | |
| (2,887,500 | ) |
Underwriter’s Discount at 2% of gross proceeds | |
| — | | |
| — | | |
| — | | |
| — | | |
| (1,650,000 | ) | |
| — | | |
| (1,650,000 | ) |
Other deferred offering costs | |
| — | | |
| — | | |
| — | | |
| — | | |
| (567,815 | ) | |
| — | | |
| (567,815 | ) |
Initial measurement of Class A ordinary shares subject to possible redemption under ASC 480-10-S99 against additional paid in capital | |
| (8,250,000 | ) | |
| (825 | ) | |
| — | | |
| — | | |
| (72,525,774 | ) | |
| — | | |
| (72,526,599 | ) |
Allocation of offering costs to Class A ordinary shares subject to possible redemption | |
| — | | |
| — | | |
| — | | |
| — | | |
| 4,488,135 | | |
| — | | |
| 4,488,135 | |
Remeasurement adjustment on Class A ordinary shares subject to possible redemption | |
| — | | |
| — | | |
| — | | |
| — | | |
| (14,480,964 | ) | |
| (1,630,572 | ) | |
| (16,111,536 | ) |
Forfeiture of Class B ordinary shares | |
| — | | |
| — | | |
| (93,750 | ) | |
| (10 | ) | |
| 10 | | |
| — | | |
| — | |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (30,847 | ) | |
| (30,847 | ) |
Balance as of June 30, 2022 | |
| 510,000 | | |
$ | 51 | | |
| 2,062,500 | | |
$ | 206 | | |
$ | — | | |
$ | (1,672,762 | ) | |
$ | (1,672,505 | ) |
The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.
DENALI CAPITAL ACQUISITION CORP.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND FOR THE PERIOD FROM JANUARY 5, 2022
(INCEPTION) THROUGH JUNE 30, 2022
| |
Six Months Ended June 30, 2023 | | |
From January 5, 2022 (Inception) Through June 30, 2022 | |
Cash flows from operating activities: | |
| | |
| |
Net loss | |
$ | (551,393 | ) | |
$ | (42,190 | ) |
Formation costs paid by the related party | |
| - | | |
| 11,343 | |
Income on Trust Account | |
| (1,938,505 | ) | |
| (114,831 | ) |
Changes in current assets and liabilities: | |
| | | |
| | |
Prepaid expenses | |
| 42,764 | | |
| (153,770 | ) |
Accounts payable and accrued expenses | |
| 2,044,562 | | |
| 80,803 | |
Accrued interest expense – related party | |
| 4,449 | | |
| - | |
Net cash used in operating activities | |
| (398,123 | ) | |
| (218,645 | ) |
| |
| | | |
| | |
Cash flows from investing activities: | |
| | | |
| | |
Investment held in Trust Account | |
| (825,000 | ) | |
| (84,150,000 | ) |
Net cash used investing activities | |
| (825,000 | ) | |
| (84,150,000 | ) |
| |
| | | |
| | |
Cash flows from financing activities: | |
| | | |
| | |
Proceeds from issuance of promissory note to related party | |
| 412,500 | | |
| 80,000 | |
Payment of promissory note to related party | |
| - | | |
| (80,000 | ) |
Proceeds from related party | |
| - | | |
| 25,000 | |
Payment to related party | |
| - | | |
| (160,020 | ) |
Proceeds from issuance of Private Placement Units | |
| - | | |
| 5,100,000 | |
Proceeds from issuance of Public Units through public offering | |
| - | | |
| 82,500,000 | |
Payment of offering costs | |
| - | | |
| (337,638 | ) |
Payment of underwriter’s discount | |
| - | | |
| (1,650,000 | ) |
Net cash provided by financing activities | |
| 412,500 | | |
| 85,477,342 | |
| |
| | | |
| | |
Net change in cash | |
| (810,623 | ) | |
| 1,108,697 | |
Cash at beginning of period | |
| 819,747 | | |
| - | |
Cash at end of period | |
$ | 9,125 | | |
$ | 1,108,697 | |
| |
| | | |
| | |
Supplemental information for non-cash financing activities: | |
| | | |
| | |
Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares | |
$ | - | | |
$ | 25,000 | |
Deferred offering cost settled through the related party payables | |
$ | - | | |
$ | 203,677 | |
Deferred offering cost included due to accrued liabilities | |
$ | - | | |
$ | 1,500 | |
Deferred offering cost charged to additional paid in capital | |
$ | - | | |
$ | 567,815 | |
Allocation of offering costs to Class A ordinary shares subject to redemption | |
$ | - | | |
$ | 4,488,135 | |
Reclassification of Class A ordinary shares subject to redemption | |
$ | - | | |
$ | 72,526,599 | |
Remeasurement adjustment on Class A ordinary shares subject to possible redemption | |
$ | 2,763,505 | | |
$ | 16,111,536 | |
Deferred underwriter fee charged to additional paid in capital | |
$ | - | | |
$ | 2,887,500 | |
Forfeiture of Class B ordinary shares | |
$ | - | | |
$ | 10 | |
The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.
DENALI CAPITAL ACQUISITION CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2023
(Unaudited)
NOTE 1 – ORGANIZATION AND BUSINESS OPERATION
Denali Capital Acquisition Corp. (the “Company”)
is a newly organized blank check company incorporated in the Cayman Islands on January 5, 2022. The Company was formed for the purpose
of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or
more businesses (a “Business Combination”).
As of June 30, 2023, the Company had not commenced
any operations. All activity for the period from January 5, 2022 (inception) through June 30, 2023, relates to the Company’s organizational
activities, those necessary to prepare for and complete the initial public offering (“IPO”), identifying a target company
for a business combination, and activities in connection with the proposed Longevity Business Combination. The Company does not expect
to generate any operating revenues until after the completion of an initial Business Combination. The Company is generating non-operating
income in the form of income from the investment of proceeds derived from the IPO. The Company has selected December 31 as its fiscal
year end.
The Company’s sponsor is Denali Capital
Global Investments LLC, a Cayman Islands limited liability company (the “Sponsor”).
Financing
The registration statement for the Company’s
IPO became effective on April 6, 2022. On April 11, 2022, the Company consummated the IPO of 8,250,000 units (including over-allotment
of 750,000 units) (“Public Units”). Each Public Unit consists of one Class A ordinary share, $0.0001 par value per share (such
shares included in the Public Units, the “Public Shares”), and one redeemable warrant (the “Public Warrants”),
each whole Public Warrant entitling the holder thereof to purchase one Public Share at an exercise price of $11.50 per share. The Public
Units were sold at a price of $10.00 per Public Unit, generating gross proceeds of $82,500,000, which is described in Note 3. Simultaneously
with the closing of the IPO, the Company consummated the sale of 510,000 units (including over-allotment of 30,000 units) (the “Private
Placement Units”) to the Sponsor at a price of $10.00 per Private Placement Unit in a private placement generating gross proceeds
of $5,100,000, which is described in Note 4. Transaction costs amounted to $5,105,315, consisting of $1,650,000 of underwriting fees,
$2,887,500 of deferred underwriters’ fees and $567,815 of other offering costs, and were all initially charged to shareholders’
equity.
Trust Account
Following the consummation of the IPO on April
11, 2022, a total of $84,150,000 of the net proceeds from the IPO and the sale of the Private Placement Units was deposited in a
trust account (the “Trust Account”). The net proceeds were invested in U.S. government securities, within the meaning set
forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity
of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund and meeting certain conditions
under Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of (i) the completion of a Business Combination
or (ii) the distribution of the funds in the Trust Account to the Company’s shareholders, as described below. Further, on April 12, 2023, the Company issued a press release announcing that it deposited $825,000 into the
Trust Account, 50% of this amount being a loan from the Sponsor in the form of a convertible promissory note and other 50% amount was
transferred directly from the remaining cash on hand balance at that time, in order to extend the period of time it has to consummate
a business combination by an additional three months, from then current deadline of April 11, 2023 to July 11, 2023.
The Company’s management has broad discretion with respect to
the specific application of the net proceeds of the IPO and the sale of the Private Placement Units, although substantially all of the
net proceeds are intended to be applied generally toward consummating a Business Combination. The stock exchange listing rules require
that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of
the value of the assets held in the Trust Account (excluding any deferred underwriters’ fees and taxes payable on the interest income
earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires
50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business
sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that
the Company will be able to successfully effect a Business Combination.
Business Combination
The Company will provide the holders of the outstanding
Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares either (i)
in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer in connection with
the Business Combination. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a
tender offer will be made by the Company. The Public Shareholders will be entitled to redeem their Public Shares for a per-share price,
payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation
of the initial Business Combination (initially anticipated to be $10.20 per Public Unit, plus any pro rata interest then in the Trust
Account, net of taxes payable). The Public Shares subject to redemption were recorded at a redemption value and classified as temporary
equity upon the completion of the IPO in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting
Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”).
The Company will not redeem Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001 (so that it
does not then become subject to the “penny stock” rules of the Securities and Exchange Commission (the “SEC”))
either prior to or upon consummation of an initial Business Combination. However, a greater net tangible asset or cash requirement may
be contained in the agreement relating to the Business Combination. The Company initially had until April 11, 2023, 12 months from the
closing of the IPO to complete the initial Business Combination (the “Combination Period”). However, on April 11, 2023, and
then further on July 11, 2023, the Company extended the Combination Period by an additional three months each, from the deadline
of April 11, 2023 to October 11, 2023 (refer to Note 9). If the Company is unable to complete the initial Business Combination within
the Combination Period, 18 months from the closing of the IPO, the Company will: (i) cease all operations except for the purpose of winding
up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price,
payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the
Trust Account and not previously released to the Company to pay the Company’s franchise and income taxes, if any (less up to $100,000
of interest to pay dissolution expenses), divided by the number of then-issued and outstanding Public Shares, which redemption will completely
extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any),
subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s
remaining shareholders and its board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under
Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights
or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete
the Business Combination within the Combination Period.
The founder shares are designated as Class B ordinary
shares (the “founder shares”) and, except as described below, are identical to the Public Shares, and holders of founder shares
have the same shareholder rights as Public Shareholders, except that (i) prior to the Company’s initial Business Combination, only
holders of the founder shares have the right to vote on the appointment of directors, including in connection with the completion of the
Company’s initial Business Combination, and holders of a majority of the founder shares may remove a member of the board of directors
for any reason, (ii) the founder shares are subject to certain transfer restrictions, as described in more detail below, (iii) the Company’s
initial shareholders have entered into an agreement with the Company, pursuant to which they have agreed to (A) waive their redemption
rights with respect to their founder shares and Public Shares in connection with the completion of the Company’s initial Business
Combination, (B) waive their redemption rights with respect to their founder shares and Public Shares in connection with a shareholder
vote to approve an amendment to the Company’s amended and restated memorandum and articles of association that would affect the
substance or timing of the Company’s obligation to provide for the redemption of the Company’s Public Shares in connection
with an initial Business Combination or to redeem 100% of the Company’s Public Shares if the Company has not consummated an initial
Business Combination by October 11, 2023, 18 months from the closing of the IPO (refer to Note 9) and (C) waive their rights to liquidating
distributions from the Trust Account with respect to their founder shares if the Company fails to complete its initial Business Combination
by October 11, 2023, 18 months from the closing of the IPO (refer to Note 9), although they will be entitled to liquidating distributions
from the Trust Account with respect to any Public Shares they hold if the Company fails to complete its initial Business Combination within
the prescribed time frame, (iv) the founder shares will automatically convert into Public Shares concurrently with or immediately following
the consummation of the Company’s initial Business Combination, or earlier at the option of the holder thereof, and (v) the founder
shares are entitled to registration rights. If the Company submits its initial Business Combination to its Public Shareholders for a vote,
the Sponsor and each member of the Company’s management team have agreed to vote their Founder Shares and Public Shares in favor
of the Company’s initial Business Combination.
The Sponsor has agreed that it will be liable
to the Company if and to the extent any claims by a third party (other than the Company’s registered public accounting firm) for
services rendered or products sold to the Company, or by a prospective target business with which the Company has discussed entering into
a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.20 per Public Share or (ii) the
actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.20 per
Public Share due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes.
This liability will not apply with respect to any claims by a third party or prospective target business who executed a waiver of any
and all rights to seek access to the Trust Account, nor will it apply to any claims under the Company’s indemnity of the underwriters
of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended, (the “Securities Act”).
Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Company’s Sponsor will
not be responsible to the extent of any liability for such third party claims.
On January 25, 2023, the Company entered into
an Agreement and Plan of Merger (the “Merger Agreement”), by and among Longevity Biomedical, Inc., a Delaware corporation
(“Longevity”), Denali SPAC Holdco, Inc., a Delaware corporation and direct, wholly owned subsidiary of the Company (“New
PubCo”), Denali SPAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of New PubCo (“Denali Merger
Sub”), Longevity Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of New PubCo (“Longevity Merger
Sub”), and Bradford A. Zakes, solely in the capacity as seller representative (the “Seller Representative”).
Pursuant to the Merger Agreement, the parties
thereto will enter into a business combination transaction (the “Longevity Business Combination” and, together with the other
transactions contemplated by the Merger Agreement, the “Transactions”), pursuant to which, among other things, immediately
following the consummation of the acquisitions by Longevity of each of Cerevast Medical, Inc., Aegeria Soft Tissue LLC, and Novokera LLC,
(i) Denali Merger Sub will merge with and into the Company (the “Denali Merger”), with the Company as the surviving entity
of the Denali Merger, and (ii) Longevity Merger Sub will merge with and into Longevity (the “Longevity Merger”), with Longevity
as the surviving company of the Longevity Merger. Following the Mergers, each of Longevity and the Company will be a subsidiary of New
PubCo, and New PubCo will become a publicly traded company. At the closing of the Transactions (the “Closing”), New PubCo
will change its name to Longevity Biomedical, Inc., and its common stock is expected to list on the Nasdaq Capital Market under the ticker
symbol “LBIO.”
The consummation of the proposed Longevity Business Combination is
subject to certain conditions as further described in the Merger Agreement.
Although there is no assurance that the Company
will be able to successfully effect a Business Combination, the Business Combination is expected to be consummated after the required
approval by the shareholders of the Company and the satisfaction of certain other conditions.
In connection with the execution of the Merger
Agreement, the sole stockholder of Longevity (the “Voting Stockholder”) has entered into a Voting and Support Agreement (the
“Longevity Support Agreement”), pursuant to which the Voting Stockholder has agreed to, among other things, (i) vote in favor
of the Merger Agreement and the transactions contemplated thereby and (ii) be bound by certain other covenants and agreements related
to the Transactions. The Voting Stockholder holds sufficient shares of Longevity to cause the approval of the Transactions on behalf of
Longevity.
In connection with the execution of the Merger
Agreement, the Company, Longevity and the Sponsor have entered into a Voting and Support Agreement (the “Sponsor Support Agreement”).
The Sponsor Support Agreement provides that the Sponsor agrees (i) to vote in favor of the proposed transactions contemplated by the Merger
Agreement, (ii) to appear at the purchaser special meeting for purposes of constituting a quorum, (iii) to vote against any proposals
that would materially impede the proposed transactions contemplated by the Merger Agreement, (iv) to not redeem any of the Company’s
ordinary shares held by it that may be redeemed, and (v) to waive any adjustment to the conversion ratio set forth in the Company’s
amended and restated memorandum and articles of association with respect to the Class B ordinary shares of the Company held by the Sponsor,
in each case, on the terms and subject to the conditions set forth in the Sponsor Support Agreement.
In support of the Transactions, the Sponsor and
FutureTech Capital LLC, a Delaware limited liability company and an entity controlled by Yuquan Wang, the Chairman of the Board of Longevity
(“FutureTech”), entered into a Sponsor Membership Interest Purchase Agreement dated November 8, 2022 (the “MIPA”). FutureTech
currently holds notes payable from Longevity that are convertible into shares of Longevity common stock, and is also an affiliate of a
significant group of stockholders of Cerevast Medical, Inc. Pursuant to the MIPA, FutureTech agreed to purchase 625,000 Class B units
of membership interests in the Sponsor (“Sponsor Membership Units”) for a total purchase price of $5 million, $2 million of
which had been paid in exchange for 250,000 Sponsor Membership Units as of the date of the Merger Agreement. Pursuant to the
MIPA, FutureTech has agreed to pay the $3 million balance of the purchase price for the remaining 375,000 Sponsor Membership Units
no later than two business days prior to the closing of the Longevity Business Combination. Each Sponsor Membership Unit
entitles FutureTech to receive one Class B ordinary share held by the Sponsor, each of which will convert into one share of New PubCo
common stock at the closing of the Longevity Business Combination. FutureTech also agreed pursuant to the MIPA to pay any extension
fees required to extend the time to close the Longevity Business Combination and to reimburse the Sponsor’s incurred expenses
related to the Longevity Business Combination if the Longevity Business Combination does not close.
On January 26, 2023, the Company filed a Form
8-K/A with the SEC to report the Merger Agreement and other legal agreements relating to the Longevity Business Combination.
On March 29, 2023, Denali SPAC HoldCo, Inc. filed
a Form S-4 with the SEC to register shares of its common stock that will be issued in connection with the business combination contemplated
by the Merger Agreement.
On April 11, 2023, the parties to the Merger Agreement
and the Sponsor entered into an Amendment to and Consent under the Merger Agreement (the “Amendment”). The Amendment provides
for the consent from the Company and the Seller Representative to the execution and issuance of the Convertible Promissory Note (as defined
below) by the Company and amends the Merger Agreement to provide that the repayment of such Convertible Promissory Note by the Company
at the closing of the business combination will not be given effect when calculating the Minimum Cash Amount (as defined in the Merger
Agreement) for purposes of the minimum cash closing condition.
On April 11, 2023, the Company issued a convertible
promissory note (the “Convertible Promissory Note”) in the total principal amount of up to $825,000 to the Sponsor. The Convertible
Promissory Note was issued with an initial principal balance of $412,500, with the remaining $412,500 drawable at the Company’s
request prior to the maturity of the Convertible Promissory Note. The Convertible Promissory Note bears an interest equivalent to the
lowest short-term Applicable Federal Rate, and matures upon the earlier of (i) the closing of the Company’s initial business combination
and (ii) the date of the liquidation of the Company. At the option of the Sponsor, upon consummation of a business combination, the Convertible
Promissory Note may be converted in whole or in part into additional Class A ordinary shares of the Company, at a conversion price of
$10 per ordinary share (the “Conversion Shares”). The terms of the Conversion Shares will be identical to those of the private
placement shares issuable upon conversion of the Private Placement Units that were issued to the Sponsor in connection with the IPO (the
“Private Placement Shares”). In the event that we do not consummate a business combination, the Convertible Promissory Note
will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven.
On April 12, 2023, the Company issued a
press release announcing that it deposited $825,000 into the Trust Account, 50% of this amount being a loan from the
Sponsor in the form of a convertible promissory note and other 50% amount was transferred directly from the remaining cash on hand balance at that time, in order to extend the period of time it has to consummate a business
combination by an additional three months, from the then current deadline of April 11, 2023 to July 11, 2023.
On May 31, 2023, Denali SPAC HoldCo, Inc. filed
an amendment to Form S-4 with the SEC to register shares of its common stock that will be issued in connection with the business combination
contemplated by the Merger Agreement.
On July 11, 2023, the Company issued a convertible
promissory note (the “FutureTech Convertible Promissory Note”) in the total principal amount of $825,000 to FutureTech. The
FutureTech Convertible Promissory Note bears an interest equivalent to the lowest short-term Applicable Federal Rate and matures upon
the earlier of (i) the closing of the Company’s initial business combination and (ii) the date of the liquidation of the Company.
At the option of FutureTech, upon consummation of a business combination, the FutureTech Convertible Promissory Note may be converted
in whole or in part into Conversion Shares. The terms of the Conversion Shares will be identical to those of the Private Placement Shares.
In the event that the Company does not consummate a business combination, the FutureTech Convertible Promissory Note will be repaid only
from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven.
On July 13, 2023, the Company issued a press
release announcing that an aggregate of $825,000 had been deposited into the Company’s Trust Account, this amount being a loan from the FutureTech Convertible Promissory
Note issued on July 11, 2023, in order to extend the period of time it has to
consummate a business combination by an additional three months, from then current deadline of July 11, 2023 to October 11, 2023
(the “Extension”).
On July 13, 2023, Denali SPAC HoldCo, Inc. filed
another amendment to Form S-4 with the SEC to register shares of its common stock that will be issued in connection with the business
combination contemplated by the Merger Agreement.
On July 18, 2023, the Sponsor lent another $80,000
to the Company, resulting in the principal amount of the Convertible Promissory Note being increased to $492,500 and the available borrowing
capacity being reduced to $332,500.
Liquidity, Capital Resources and Going Concern
Consideration
The Company’s liquidity needs prior to the
consummation of the IPO had been satisfied through a payment from the Sponsor of $25,000 (see Note 5) for the founder shares and the loan
under an unsecured promissory note (the “Promissory Note”) from the Sponsor of up to $400,000 (see Note 5) which was fully
repaid on April 12, 2022. Subsequent to the consummation of the IPO and sale of the Private Placement Units on April 11, 2022, a total
of $84,150,000 was placed in the Trust Account, and the Company had $1,515,795 of cash held outside of the Trust Account, after
payment of costs related to the IPO, and available for working capital purposes. In connection with the IPO, the Company incurred $5,105,315
in transaction costs, consisting of $1,650,000 of underwriting fees, $2,887,500 of deferred underwriting fees and $567,815 of other offering
costs.
As of June 30, 2023, the Company had marketable
securities held in the Trust Account of $88,135,105. The Company intends to use substantially all of the funds held in the Trust Account,
including any amounts representing interest earned on the Trust Account (less income taxes payable), to complete the Business Combination.
To the extent that the Company’s share capital or debt is used, in whole or in part, as consideration to complete a Business Combination,
the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses,
make other acquisitions and pursue the Company’s growth strategies.
As of June 30, 2023, the Company had cash of $9,125
outside of the Trust Account. If the Company does not complete the Longevity Business Combination, it intends to use the funds held outside
the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses,
travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review
corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a Business Combination.
As described above, on January 25, 2023, the Company
entered into a Merger Agreement, by and among Longevity, New PubCo, Denali Merger Sub, Longevity Merger Sub, and the Seller Representative.
As of June 30, 2023, the Company had a working deficit of $3,698,702. In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). If the Company completes the initial Business Combination, it would repay such loaned amounts without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into units of the post Business Combination entity at a price of $10.00 per unit. The units would be identical to the Private Placement Units. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside of the Trust Account to repay such loaned amounts, but no proceeds from the Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into units of the post-business combination entity, at a price of $10.00 per unit at the option of the lender. The units would be identical to the Private Placement Units. On April 11, 2023, the Company issued the Convertible Promissory Note in the total principal amount of up to $825,000 to the Sponsor. The Convertible Promissory Note was issued with an initial principal balance of $412,500, with the remaining $412,500 drawable at the Company’s request prior to the maturity of the Convertible Promissory Note. As of June 30, 2023, there was an amount of $412,500 outstanding under Working Capital Loans in the form of the Convertible Promissory Note. Further, an amount of $4,449 with interest at 4.86% on amount borrowed
from the Sponsor for the Extension was recognized as accrued interest expense – related party as of June 30, 2023 and interest expense
– related party under other (income)/expenses for the three and six months ended June 30, 2023 in unaudited condensed consolidated
statements of operations. On July 11, 2023, the Company issued a FutureTech Convertible Promissory Note in the total principal amount
of $825,000 to FutureTech and 100% of such amount has been utilized to fund the required payment in order to extend the period of time
to consummate a business combination from then current deadline of July 11, 2023 to October 11, 2023. On July 18, 2023, the Sponsor lent another $80,000 to the Company, resulting in the principal amount of the Convertible Promissory Note being increased to $492,500 and the available borrowing capacity being reduced to $332,500.
Based on the foregoing, management believes that
the Company will not have sufficient working capital and borrowing capacity to meet its needs through the consummation of the initial
Business Combination. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve
liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction,
and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable
terms, if at all.
In accordance with ASC Subtopic 205-40,
“Presentation of Financial Statements – Going Concern”, the Company has evaluated that there are certain
conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a
going concern through October 11, 2023 (refer to Note 9), the date that the Company will be required to cease all operations,
except for the purpose of winding up, if a Business Combination is not consummated. These consolidated financial statements do not
include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be
necessary should the Company be unable to continue as a going concern.
Risks and Uncertainties
In February 2022, the Russian Federation and
Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United
States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and
related sanctions on the world economy are not determinable as of the date of these consolidated financial statements. The specific
impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of
these condensed consolidated financial statements.
Management continues to evaluate the impact of
the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus and war could have a negative effect on the
Company’s financial position, results of its operations and search for a target company, the specific impact is not readily determinable
as of the date of these condensed consolidated financial statements.
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES
Basis of Presentation
The accompanying unaudited condensed
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and
Article 8 of Regulation S-X under the Securities Act. Certain information or footnote disclosures normally included in financial
statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for
interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete
presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited
condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary
for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The accompanying unaudited condensed
consolidated financial statements should be read in conjunction with the Company’s report on Form 10-K filed with the SEC on
March 17, 2023. The condensed consolidated Balance Sheet as of December 31, 2022 presented in this Form 10-Q has been derived from
the audited Balance Sheet filed in the aforementioned Form 10-K. The interim results for the three and six months ended June 30,
2023 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2023 or for any future
interim periods.
Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements
include the accounts of the Company and its wholly owned subsidiaries. Any intercompany transactions and balances have been eliminated
in consolidation.
Emerging Growth Company Status
The Company is an “emerging growth company,”
as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, (the “JOBS Act”),
and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports
and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act
exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private
companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of
securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply
with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended
transition period and comply with the requirements that apply to non-emerging growth companies, but any such election to opt out is
irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued
or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can
adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the
Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an
emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.
Use of Estimates
The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of income and expenses during the reporting period. Accordingly, the
actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments
with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents
on June 30, 2023 and December 31, 2022.
Investment Held in Trust Account
The Company’s portfolio of investment held
in the Trust Account is comprised of an investment in money market funds that invest in U.S. government securities and generally have
a readily determinable fair value. Gains and losses resulting from the change in fair value of these securities are included in income
on Trust Account in the accompanying condensed consolidated statements of operations. The estimated fair values of investment
held in the Trust Account are determined using available market information.
Offering Costs
Offering costs incurred during the three months
ended June 30, 2022 were $5,105,315 consisting principally of underwriting, legal, accounting and other expenses incurred through the
balance sheet date that are related to the IPO and were initially charged to shareholders’ equity upon the completion of the IPO.
The Company complies with the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A – “Expenses of Offering”.
The Company allocates offering costs between the Public Shares and Public Warrants (as defined below in Note 3) based on the relative
fair values of the Public Shares and Public Warrants. Accordingly, $4,488,135 was allocated to the Public Shares and charged to temporary
equity, and $617,180 was allocated to Public Warrants and charged to shareholders’ deficit during the three months ended June 30, 2022.
Fair Value of Financial Instruments
The fair value of the Company’s assets and
liabilities, which qualify as financial instruments under the FASB ASC 825, “Financial Instruments,” approximates the carrying
amounts represented in the condensed consolidated balance sheet, primarily due to its short-term nature.
Warrants
The Company accounts for warrants as either equity-classified
or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance
in FASB ASC 480 and FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether
the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet
all of the requirements for equity classification under FASB ASC 815, including whether the warrants are indexed to the Company’s
own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside
of the Company’s control, among other conditions for equity classification. This assessment is conducted at the time of warrant
issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. The Company accounts for the
8,250,000 Public Warrants (as defined in Note 3) and 510,000 Private Placement Warrants (as defined in Note 4) as equity-classified
instruments.
Convertible Debt
The Company issues debt that may have conversion
features.
Convertible debt – derivative treatment
– When the Company issues debt with a conversion feature, we must first assess whether the embedded equity-linked component is clearly and closely related to its host instruments. If a component is clearly
and closely related to its host instruments, then we have to assess whether the conversion feature meets the requirements
to be treated as a derivative, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional
amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes
the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion
can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated
from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity.
The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in shareholders’ equity in its
statement of financial position.
If the conversion feature within convertible debt
meets the requirements to be treated as a derivative, we estimate the fair value of the embedded derivative using the Black Scholes method
upon the date of issuance. If the fair value of the embedded derivative is higher than the face value of the convertible debt, the excess
is immediately recognized as interest expense. The derivative shall be recorded at fair value as liability and the carrying value assigned
to the host contract represents the difference between the previous carrying amount of the hybrid instrument and the fair value of the
derivative; therefore, there is no gain or loss from the initial recognition and measurement of an embedded derivative that is accounted
for separately from its host contract.
Convertible debt – beneficial conversion
feature – If the conversion feature is not treated as a derivative, we assess whether it is a beneficial conversion feature
(“BCF”). A BCF exists if the conversion price of the convertible debt instrument is less than the share price on the commitment
date. The value of a BCF is equal to the intrinsic value of the feature, the difference between the conversion price and the class of
shares into which it is convertible and is recorded as additional paid in capital and as a debt discount in the condensed consolidated
balance sheets. The Company amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the
condensed consolidated statements of operations. If the debt is retired early, the associated debt discount is then recognized immediately
as amortization of debt discount expense in the condensed consolidated statements of operations.
Convertible debt – contingent beneficial
conversion feature – When assessing the convertible debt for BCF, we also assess whether the conversion feature meets the requirements
to be treated as contingent beneficial conversion feature (“Contingent BCF”), as follows: a) the instrument becomes convertible
only upon the occurrence of a future event outside the control of the holder; b) the instrument is convertible from inception but contains
conversion terms that change upon the occurrence of a future event. If the conversion feature is within convertible debt meets the requirement
to be treated as Contingent BCF, it shall not be recognized in the earnings until the contingency is resolved.
If the conversion feature does not qualify for
either the derivative treatment or as a BCF (including Contingent BCF), the convertible debt is treated as traditional debt.
The conversion feature in convertible promissory note issued by the Company on April 11, 2023, does not qualify for either the derivative
treatment or for BCF. These have been treated as Contingent BCF which shall not be recognized in the earnings until the contingency is resolved. These convertible promissory notes are presented as traditional
debt as of June 30, 2023 in unaudited condensed consolidated balance sheets.
Class A Ordinary Shares Subject to Possible
Redemption
The Company accounts for its Class A ordinary
shares subject to possible redemption in accordance with ASC 480. Class A ordinary shares subject to mandatory redemption (if any) are classified
as a liability instrument and measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption
rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within
the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’
equity. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s
control and are subject to the occurrence of uncertain future events. Accordingly, as of June 30, 2023 and December 31, 2022, 8,250,000
Class A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’
deficit section of the Company’s condensed consolidated balance sheets.
The Company recognizes changes in redemption value
immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each
reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional
paid-in capital or accumulated deficit if additional paid-in capital equals to zero.
As of June 30, 2023 and December 31, 2022,
the ordinary shares reflected in the condensed consolidated balance sheets are reconciled in the following table:
Gross proceeds from the IPO | |
$ | 82,500,000 | |
Less: | |
| | |
| |
| | |
Proceeds allocated to Public Warrants | |
| (9,973,401 | ) |
Allocation of offering costs related to redeemable shares | |
| (4,488,135 | ) |
| |
| | |
Plus: | |
| | |
Initial measurement of carrying value to redemption value | |
| 16,111,536 | |
Subsequent measurement of Class A ordinary shares subject to possible redemption (income earned on Trust Account) | |
| 1,221,600 | |
Ordinary shares subject to possible redemption – December 31, 2022 | |
| 85,371,600 | |
Subsequent measurement of Class A ordinary shares subject to possible redemption (income earned on Trust Account) | |
| 912,646 | |
Ordinary shares subject to possible redemption – March 31, 2023 | |
| 86,284,246 | |
Subsequent measurement of Class A ordinary shares
subject to possible redemption (income earned on Trust Account) | |
| 1,025,859 | |
Subsequent measurement of Class A ordinary shares subject to possible
redemption (extension deposit) | |
| 825,000 | |
Ordinary shares subject to possible redemption – June 30, 2023 | |
$ | 88,135,105 | |
Concentration of Credit Risk
Financial instruments that potentially subject
the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal
Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account.
Net Income/(Loss) Per Ordinary Share
The Company complies with the accounting and disclosure
requirements of FASB ASC 260, “Earnings Per Share.” Net loss per redeemable and non-redeemable ordinary share is computed
by dividing net loss by the weighted average number of ordinary shares outstanding between the redeemable and non-redeemable shares during
the period, excluding ordinary shares subject to forfeiture. Weighted average shares were reduced for the effect of an aggregate of 93,750
founder shares that were forfeited during the three months ended June 30, 2022, due to the underwriters’ partial exercise of
their over-allotment option. In order to determine the net income (loss) attributable to both the redeemable shares and non-redeemable
shares, the Company first considered the undistributed income (loss) allocable to both the redeemable shares and non-redeemable shares
and the undistributed income (loss) is calculated using the total net loss less dividends paid. The Company then allocated the undistributed
income (loss) based on the weighted average number of shares outstanding between the redeemable and non-redeemable shares.
Subsequent measurement adjustments recorded pursuant to ASC 480-10-S99-3A
related to redeemable shares are treated in the same manner as dividends on non-redeemable shares. Class A ordinary shares are redeemable
at a price determined by the Trust Account held by the Company. This redemption price is not considered a redemption at fair value. Accordingly,
the adjustments to the carrying amount are reflected in the Earnings Per Share (“EPS”) using the two-class method. The Company
has elected to apply the two-class method by treating the entire periodic adjustment to the carrying amount of the Class A ordinary shares
subject to possible redemption like a dividend.
Based on the above, any remeasurement of
redemption value of the Class A ordinary shares subject to possible redemption is considered to be dividends paid to the Public
Shareholders. Warrants issued are contingently exercisable (i.e., on the later of 30 days after the completion of the initial
Business Combination or 12 months from the closing of the IPO). Further, Convertible Promissory Notes are also contingently
exercisable upon the consummation of the initial Business Combination. For EPS purpose, the warrants and convertible promissory note
are anti-dilutive since they would generally not be reflected in basic or diluted EPS until the contingency is resolved. As of June
30, 2023 and 2022, the Company did not have any other dilutive securities and other contracts that could, potentially, be
exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted income (loss) per
ordinary share is the same as basic earnings (loss) per ordinary share for the periods presented.
The net income (loss) per share presented in the unaudited condensed consolidated
statements of operations is based on the following:
| |
Three
months ended June 30, 2023 | | |
Six
months ended June 30, 2023 | | |
Three
months ended June 30,
2022 | | |
January 5, 2022 (Inception) to June 30, 2022 | |
Net income/(loss) | |
$ | 457,709 | | |
$ | (551,393 | ) | |
$ | (30,847 | ) | |
$ | (42,190 | ) |
Accretion of temporary equity to redemption value | |
| (1,850,859 | ) | |
| (2,763,505 | ) | |
| (16,111,536 | ) | |
| (16,111,536 | ) |
Net loss including accretion of temporary equity | |
$ | (1,393,150 | ) | |
$ | (3,314,898 | ) | |
$ | (16,142,383 | ) | |
$ | (16,153,726 | ) |
| |
Three months
ended June 30,
2023 | | |
Six months
ended June 30,
2023 | | |
Three months
ended June 30,
2022 | | |
January 5,
2022
(Inception)
to June 30,
2022 | |
| |
Redeemable | | |
Non-
Redeemable | | |
Redeemable | | |
Non-
Redeemable | | |
Redeemable | | |
Non-
Redeemable | | |
Redeemable | | |
Non-
Redeemable | |
Particulars | |
Shares | | |
Shares | | |
Shares | | |
Shares | | |
Shares | | |
Shares | | |
Shares | | |
Shares | |
Basic and diluted net income/(loss) per share: | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Numerators: | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Allocation of net loss including accretion of temporary equity | |
| (1,061,999 | ) | |
| (331,151 | ) | |
| (2,526,949 | ) | |
| (787,949 | ) | |
| (12,047,664 | ) | |
| (4,094,719 | ) | |
| (10,770,521 | ) | |
| (5,383,205 | ) |
Accretion of temporary equity to redemption value | |
| 1,850,859 | | |
| — | | |
| 2,763,505 | | |
| — | | |
| 16,111,536 | | |
| — | | |
| 16,111,536 | | |
| — | |
Allocation of net income/(loss) | |
| 788,860 | | |
| (331,151 | ) | |
| 236,556 | | |
| (787,949 | ) | |
| 4,063,872 | | |
| (4,094,719 | ) | |
| 5,341,015 | | |
| (5,383,205 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Denominators: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Weighted-average shares outstanding | |
| 8,250,000 | | |
| 2,572,500 | | |
| 8,250,000 | | |
| 2,572,500 | | |
| 7,343,407 | | |
| 2,495,852 | | |
| 3,775,424 | | |
| 1,886,992 | |
Basic and diluted net income/(loss) per share | |
| 0.10 | | |
| (0.13 | ) | |
| 0.03 | | |
| (0.31 | ) | |
| 0.55 | | |
| (1.64 | ) | |
| 1.41 | | |
| (2.85 | ) |
Income Taxes
The Company accounts for income taxes under FASB
ASC 740, “Income Taxes” (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for
both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected
future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be
established when it is more likely than not that all or a portion of deferred tax assets will not be realized.
ASC 740 also clarifies the accounting for uncertainty
in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process
for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits
to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides
guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.
The Company recognizes accrued interest and penalties
related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest
and penalties as of June 30, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result
in significant payments, accruals or material deviation from its position.
The Company determined that the Cayman Islands
is the Company’s only major tax jurisdiction and the location of all members of management, sponsors, directors, any employees,
or assets to the extent employed is the United States.
The Company may be subject to potential examination
by federal and state taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing
and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s
management does not expect that the total amount of unrecognized tax benefits will materially change over the next 12 months.
There is currently no taxation imposed on income
by the Government of the Cayman Islands for the six months ended June 30, 2023 and for the period from January 5, 2022 (inception) through
June 30, 2022.
Recent Accounting Pronouncements
In August 2020, the FASB issued Accounting
Standards Update (“ASU”) No. 2020-06, “Debt — Debt with Conversion and Other Options (Subtopic 470-20)
and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments
and Contracts in an Entity’s Own Equity (“ASU 2020-06”)”, which simplifies accounting for convertible
instruments by removing major separation models required under current U.S. GAAP. The ASU also removes certain settlement conditions
that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings
per share calculation in certain areas. ASU 2020-06 is effective January 1, 2024 and should be applied on a full or
modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing
the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.
Management does not believe that any other
recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s
consolidated financial statements.
NOTE 3 – INITIAL PUBLIC OFFERING
On April 11, 2022, the Company consummated the
IPO of 8,250,000 Public Units, inclusive of 750,000 Public Units issued pursuant to the underwriters’ partial exercise of their
over-allotment option. The Public Units were sold at a purchase price of $10.00 per Public Unit, generating gross proceeds of $82,500,000.
Each Public Unit consists of one Public Share and one Public Warrant. Each Public Warrant entitles the holder thereof to purchase one
Public Share at a price of $11.50 per share.
The warrants will become exercisable on the later
of 30 days after the completion of the Company’s initial Business Combination or 12 months from the closing of the IPO and will
expire five years after the completion of the Company’s initial Business Combination or earlier upon redemption or liquidation (see
Note 7).
NOTE 4 – PRIVATE PLACEMENT
Simultaneously with the closing of the IPO, the
Company consummated a private placement and the Sponsor purchased an aggregate of 510,000 Private Placement Units (including 30,000
Private Placement Units pursuant to the underwriters’ partial exercise of the over-allotment option) at a price of $10.00 per Private
Placement Unit, generating gross proceeds to the Company of $5,100,000. Each whole Private Placement Unit consists of one Class
A ordinary share (“Private Placement Shares”) and one warrant (“Private Placement Warrants”). Each Private Placement
Warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. Certain of the
proceeds from the sale of the Private Placement Units were added to the net proceeds from the IPO held in the Trust Account.
If the Company does not complete a Business Combination
within 18 months from the closing of the IPO (refer to Note 9), the proceeds from the sale of the Private Placement Units held in the
Trust Account will be used to fund the redemption of the Company’s Class A ordinary shares (subject to the requirements of applicable
law) and the Private Placement Units and all underlying securities will expire worthless. The Private Placement Units will not be transferable,
assignable, or saleable until 30 days after the completion of an initial Business Combination, subject to certain exceptions.
NOTE 5 – RELATED PARTY TRANSACTIONS
Founder Shares
On February 3, 2022, the Company issued an aggregate
of 2,156,250 founder shares to the Sponsor in exchange for a payment of $25,000 from the Sponsor for deferred offering
costs. In March 2022, the Sponsor transferred 20,000 founder shares to the Chief Financial Officer of the Company and 110,000 founder
shares to certain members of the Company’s board of directors. On May 23, 2022, 93,750 founder shares were forfeited by the Sponsor
as the underwriters did not exercise their over-allotment option on the remaining 375,000 Public Units (see Note 6), resulting in
the Sponsor holding a balance of 1,932,500 founder shares.
The founder shares are identical to the Class
A ordinary shares included in the units sold in the IPO, except that the founder shares will automatically convert into Class A ordinary
shares at the time of the Company’s initial Business Combination (see Note 7). Also, the Sponsor and each member
of the Company’s management team have entered into an agreement with the Company, pursuant to which they have agreed to
waive their redemption rights with respect to any founder shares and Public Shares held by them.
The Sponsor and the Company’s directors
and executive officers have agreed not to transfer, assign or sell any of their founder shares until the earlier of (A) one year after
the completion of an initial Business Combination and (B) subsequent to the Company’s initial Business Combination, (x) if the closing
price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations,
recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after an initial
Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction
that results in all Public Shareholders having the right to exchange their Public Shares for cash, securities or other property. Any permitted
transferees would be subject to the same restrictions and other agreements of the Sponsor and the Company’s directors and executive
officers with respect to any founder shares.
The sale of the founder shares to the Company’s
Chief Financial Officer and to certain members of the Company’s board of directors is in the scope of FASB ASC Topic 718, “Compensation-Stock
Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured
at fair value upon the grant date. The fair value of the 130,000 shares granted to the Company’s directors and executive officers
was $1,005,964 or $7.74 per share. The founder shares were granted subject to a performance condition (i.e., the occurrence of a Business
Combination). Compensation expense related to the founder shares is recognized only when the performance condition is of probable
occurrence under the applicable accounting literature in this circumstance. As of June 30, 2023, the Company determined that a Business
Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized. Stock-based compensation
would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an
amount equal to the number of founder shares times the fair value per share at the grant date (unless subsequently modified) less
the amount initially received for the purchase of the founder shares.
Promissory Note - Related Party
On February 3, 2022, the Sponsor agreed to loan the Company up to $400,000
to be used for a portion of the expenses of the IPO. As of April 11, 2022, there was $80,000 outstanding under the Promissory Note. This
loan was non-interest bearing, unsecured and due at the earlier of (i) September 30, 2022 or (ii) the closing of the IPO. On April 12,
2022, the loan was repaid upon the closing of the IPO out of the offering proceeds not held in the Trust Account.
Due to the Related Party
The Sponsor paid certain formation, operating
or offering costs on behalf of the Company. These amounts were due on demand and were non-interest bearing. During the period from January
5, 2022 (inception) through March 31, 2022, the Sponsor paid $215,020 of formation, operating costs and offering costs on behalf of the
Company. On April 12, 2022, the Company paid the Sponsor $160,020 and on April 14, 2022, the Company received $25,000 from the Sponsor.
Subsequently on July 19, 2022, the Company fully paid the remaining $80,000 to the related party.
Working Capital Loan
In order to finance transaction costs in connection
with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors, may,
but are not obligated to, provide the Company Working Capital Loans. If the Company completes a Business Combination, it would repay
the Working Capital Loans out of the proceeds of the Trust Account released to the Company. In the event that a Business Combination does
not close the Company may use a portion of proceeds held outside of the Trust Account to repay the Working Capital Loans, but no
proceeds held in the Trust Account would be used for such repayment.
The Working Capital loans would either be
repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of
such Working Capital Loans may be convertible into units of the post-business combination entity at a price of $10.00 per unit. The
units would be identical to the Private Placement Units. On April 11, 2023, the Company issued the Convertible Promissory Note in
the total principal amount of up to $825,000 to the Sponsor. The Convertible Promissory Note bears an interest accruing on the
unpaid and outstanding total principal amount at the lowest short-term Applicable Federal Rate as in effect on the date thereof and
is payable in arrears on the maturity date. Interest will be calculated on the basis of a 365-day year and the actual number of days
elapsed, to the extent permitted by applicable law. The Convertible Promissory Note was issued with an initial principal balance of
$412,500, with the remaining $412,500 drawable at the Company’s request prior to the maturity of the Convertible Promissory
Note. The Company deposited $825,000 into the Trust Account, 50% of this amount being a loan from the Sponsor in the
form of a convertible promissory note and other 50% amount was transferred directly from the remaining cash on hand balance at that time,
in order to extend the period of time it has to consummate a business combination by an additional three months, from the then current
deadline of April 11, 2023 to July 11, 2023. As of June 30, 2023, Working Capital Loans equivalent to $412,500 in the form of the
Convertible Promissory Note were outstanding. Further, an amount of $4,449 with interest at 4.86% on amount borrowed
from the Sponsor for the Extension was recognized as accrued Interest expense – related party as of June 30, 2023 and interest expense
– related party under other (income)/expenses for the three and six months ended June 30, 2023 in unaudited condensed consolidated
statements of operations. As of December 31, 2022, no Working Capital Loans were outstanding. On July 18, 2023, the Sponsor lent
another $80,000 to the Company, resulting in Working Capital Loans being increased to $492,500 and the available borrowing capacity being reduced to $332,500.
NOTE 6 – COMMITMENTS AND CONTINGENCIES
Registration Rights
The holders of the founder shares, Private Placement
Shares and Private Placement Warrants, including any of those issued upon conversion of the Working Capital Loans (and
any Private Placement Shares issuable upon the exercise of the Private Placement Warrants that may be issued upon conversion of the Working
Capital Loans) will be entitled to registration rights pursuant to a registration and shareholder rights agreement signed on April 6,
2022. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register
such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements
filed after the completion of the initial Business Combination and rights to require the Company to register for resale such securities
pursuant to Rule 415 under the Securities Act. The Company will bear the costs and expenses of filing any such registration statements.
Underwriting Agreement
The underwriters received a cash
underwriting discount of $0.20 per Public Unit, or $1,650,000 in the aggregate, paid upon the closing of the IPO. In addition, the
underwriters will be entitled to a deferred fee of $0.35 per Public Unit, or $2,887,500 in the aggregate, which is included in the
accompanying condensed consolidated balance sheets. The deferred fee will become payable to the underwriters from the amounts held
in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting
agreement.
NOTE 7 – SHAREHOLDER’S DEFICIT
Preference shares – The Company
is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights
and preferences as may be determined from time to time by the Company’s board of directors. As of June 30, 2023 and December
31, 2022, there were no preference shares issued and outstanding.
Class A Ordinary Shares – The Company
is authorized to issue 200,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of June 30, 2023 and December
31, 2022, there were 510,000 Class A ordinary shares issued and outstanding, excluding 8,250,000 Class A ordinary shares subject to possible
redemption.
Class B Ordinary Shares –
The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of
$0.0001 per share. As of June 30, 2023 and December 31, 2022, there were 2,062,500 Class B ordinary shares issued and outstanding.
On May 23, 2022, 93,750 Class B ordinary shares were forfeited as the underwriters did not exercise the over-allotment option on the
remaining 375,000 Public Units.
Prior to the Company’s initial Business
Combination, only holders of Class B ordinary shares will have the right to vote on the appointment of directors and holders of a majority
of the Company’s Class B ordinary shares may remove a member of the board of directors for any reason. In addition, in a vote to
continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two-thirds of the votes of
all ordinary shares voted at a general meeting), holders of founder shares will have ten votes for every founder share and holders of
Class A ordinary shares will have one vote for every Class A ordinary share and, as a result, the Company’s initial shareholders
will be able to approve any such proposal without the vote of any other shareholder.
The Class B ordinary shares will automatically
convert into Class A ordinary shares on the consummation of the initial Business Combination at a ratio such that the number of Class
A ordinary shares issuable upon conversion of all founder shares will equal, in the aggregate, on an as-converted basis, approximately
20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the IPO, plus (ii) the total number
of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued
or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination (after giving
effect to any redemptions of Class A ordinary shares by Public Shareholders), excluding any Class A ordinary shares or equity-linked securities
exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business
Combination and any Private Placement Units issued to the Sponsor, its affiliates or any member of the Company’s management team
upon conversion of the Working Capital Loans. Any conversion of Class B ordinary shares described herein will take effect as a compulsory
redemption of Class B ordinary shares and an issuance of Class A ordinary shares as a matter of Cayman Islands law. In no event will the
Class B ordinary shares convert into Class A ordinary shares at a rate of less than one-to-one.
Warrants
All warrants (Public Warrants and Private Warrants)
will become exercisable at $11.50 per share, subject to adjustment, on the later of 30 days after the completion of the initial Business
Combination or 12 months from the closing of the IPO; provided in each case that the Company has an effective registration statement under
the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus
relating to them is available (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified
in the warrant agreement). The warrants will expire at 5:00 p.m., New York City time, five years after the completion of the initial Business
Combination or earlier upon redemption or liquidation. On the exercise of any warrant, the warrant exercise price will be paid directly
to the Company and not placed in the Trust Account.
In addition, if (x) the Company issues additional
Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of an initial Business
Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue
price to be determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates,
without taking into account any founder shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly
Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest
thereon, available for the funding of an initial Business Combination on the date of the consummation of an initial Business Combination
(net of redemptions), and (z) the volume weighted average trading price of Class A ordinary shares during the 20-trading day period starting
on the trading day prior to the day on which the Company consummates an initial Business Combination (such price, the “Market Value”)
is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher
of the Market Value or the Newly Issued Price and the $16.50 per share redemption trigger price will be adjusted (to the nearest cent)
to be equal to 165% of the higher of the Market Value or the Newly Issued Price.
The Company has not registered the Class A ordinary
shares issuable upon exercise of the warrants at this time. However, the Company has agreed that as soon as practicable, but in no event
later than 20 business days after the closing of the initial Business Combination, it will use commercially reasonable efforts to file
with the SEC a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants, and it will use commercially
reasonable efforts to cause the same to become effective within 60 business days following the initial Business Combination and to maintain
a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed. Notwithstanding the
above, if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such
that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at
its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with
Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a
registration statement, but the Company will be required to use commercially reasonable efforts to register or qualify the shares under
applicable blue sky laws to the extent an exemption is not available.
Redemption of Warrants
Once the warrants become exercisable, the Company
may redeem the outstanding warrants:
|
● |
in whole and not in part; |
| ● | at a price of $0.01 per warrant; |
|
● |
upon a minimum of 30 days’ prior written notice of redemption, which is referred to as the 30-day redemption period; and |
| ● | if, and only if, the last reported sale price of ordinary shares equals or exceeds $16.50 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
The Company will not redeem the warrants unless
a registration statement under the Securities Act covering the ordinary shares issuable upon exercise of the warrants is effective and
a current prospectus relating to those ordinary shares is available throughout the 30-day redemption period, except if the warrants may
be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act. If and when the warrants
become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying
securities for sale under all applicable state securities laws.
If the Company calls the warrants for redemption
as described above, its management will have the option to require all holders that wish to exercise warrants to do so on a “cashless
basis.” In determining whether to require all holders to exercise their warrants on a “cashless basis,” the Company’s
management will consider, among other factors, the cash position, the number of warrants that are outstanding and the dilutive effect
on the Company’s shareholders of issuing the maximum number of ordinary shares issuable upon the exercise of the Company’s
warrants. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary
shares equal to the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants,
multiplied by the excess of the “fair market value” over the exercise price of the warrants by (y) the fair market value.
The “fair market value” shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days
ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.
NOTE 8 – FAIR VALUE MEASUREMENTS
The fair value of the Company’s financial
assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale
of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the
measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of
observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions
about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities
based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
| Level 1: | Quoted prices in active markets for identical assets or
liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient
frequency and volume to provide pricing information on an ongoing basis. |
| Level 2: | Observable inputs other than Level 1 inputs. Examples
of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or
liabilities in markets that are not active. |
| Level 3: | Unobservable inputs based on our assessment of the assumptions
that market participants would use in pricing the asset or liability. |
The following tables presents information about
the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022, and indicates
the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.
| |
As of June 30, 2023 | | |
Quoted Prices in Active Markets (Level 1) | | |
Significant Other Observable Inputs (Level 2) | | |
Significant Other Unobservable Inputs (Level 3) | |
Assets: | |
| | | |
| | | |
| | | |
| | |
Investment held in Trust Account | |
$ | 88,135,105 | | |
$ | 88,135,105 | | |
| - | | |
| - | |
| |
As of December 31, 2022 | | |
Quoted Prices in Active Markets (Level 1) | | |
Significant Other Observable Inputs (Level 2) | | |
Significant Other Unobservable Inputs (Level 3) | |
Assets: | |
| | |
| | |
| | |
| |
Investment held in Trust Account | |
$ | 85,371,600 | | |
$ | 85,371,600 | | |
| - | | |
| - | |
NOTE 9 – SUBSEQUENT EVENTS
The Company has evaluated subsequent events
through the date these condensed consolidated financial statements were issued and determined that there were no significant
unrecognized events through that date other than those noted below.
On July 11, 2023, the Company issued the FutureTech
Convertible Promissory Note in the total principal amount of $825,000 to FutureTech. The FutureTech Convertible Promissory Note bears
an interest equivalent to the lowest short-term Applicable Federal Rate and matures upon the earlier of (i) the closing of the Company’s
initial business combination and (ii) the date of the liquidation of the Company. At the option of FutureTech, upon consummation of a
business combination, the FutureTech Convertible Promissory Note may be converted in whole or in part into Conversion Shares. The terms
of the Conversion Shares will be identical to those of the Private Placement Shares. In the event that the Company does not consummate
a business combination, the FutureTech Convertible Promissory Note will be repaid only from funds held outside of the Trust Account or
will be forfeited, eliminated or otherwise forgiven.
On July 13, 2023, the Company issued a press
release announcing that an aggregate of $825,000 had been deposited into the Company’s Trust Account, this amount being a loan
from the FutureTech Convertible Promissory Note issued on July 11, 2023, in order to extend the period of time it has to consummate
a business combination by an additional three months, from the then current deadline of July 11, 2023 to October 11, 2023 (the
“Extension”).
On July 11, 2023 and then again on August
11, 2023, the Company extended its directors and officers insurance policy until August 7, 2023 and September 7, 2023, respectively,
for gross premium including taxes totaling $24,691.
On July 18, 2023, the Sponsor lent another $80,000
to the Company, resulting in the principal balance of the Convertible Promissory Note being increased to $492,500 and the available borrowing capacity being reduced to $332,500.
Item 2. Management’s Discussion and Analysis
of Financial Condition and Results of Operations.
References in this report (the
“Quarterly Report”) to the “Company,” “our,” “us” or “we” refer to
Denali Capital Acquisition Corp. The following discussion and analysis of the Company’s financial condition and results of
operations should be read in conjunction with the consolidated financial statements and the notes related thereto contained
elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes
forward-looking statements that involve risks and uncertainties.
Special Note Regarding Forward-Looking Statements
This Quarterly Report includes “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, that are not historical facts, and involve risks and uncertainties that could cause actual results to
differ materially from those expected and projected. All statements, other than statements of historical fact included in this Form 10-Q
including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results
of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for
future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,”
“possible,” “potential,” “predict,” “project,” “should,” “would”
and variations thereof and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking
statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently
available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and
results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to
differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s
final prospectus for its initial public offering (“IPO”) filed with the SEC on April 7, 2022, the Annual Report on Form
10-K filed with the SEC on March 17, 2023, and the preliminary prospectus/proxy statement included in a Registration Statement on Form
S-4 filed with the SEC by Denali SPAC Holdco, Inc. on March 29, 2023, as amended by Amendments Nos. 1 and 2 thereto, filed with the SEC
on May 31, 2023 and July 13, 2023, respectively. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s
website at http://www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation
to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Overview
We are a blank check company incorporated as a
Cayman Islands exempted company on January 5, 2022 (inception), for the purpose of effecting an initial business combination. While we
will not be limited to a particular industry or geographic region in our identification and acquisition of a target company, we intend
to focus on technology, consumer and hospitality and will not complete our initial business combination with a target that is headquartered
in China (including Hong Kong and Macau) or conducts a majority of its business in China (including Hong Kong and Macau). We intend to
effectuate our initial business combination using cash from the proceeds of our IPO and the sale of units in the Private Placement to
the sponsor, additional shares, debt or a combination of cash, equity and debt.
We expect to continue to incur significant costs
in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a business combination will be successful.
Recent Developments
On January 25, 2023, we entered into an Agreement
and Plan of Merger (the “Merger Agreement”), by and among Longevity Biomedical, Inc., a Delaware corporation (“Longevity”),
Denali SPAC Holdco, Inc., a Delaware corporation and direct, wholly owned subsidiary of the Company (“New PubCo”), Denali
SPAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of New PubCo (“Denali Merger Sub”), Longevity
Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of New PubCo (“Longevity Merger Sub”), and Bradford
A. Zakes, solely in the capacity as seller representative (the “Seller Representative”).
Pursuant to the Merger Agreement, the parties
thereto will enter into the Transactions, pursuant to which, among other things, immediately following the consummation of the acquisitions
by Longevity of each of Cerevast Medical, Inc., Aegeria Soft Tissue LLC, and Novokera LLC, (i) Denali Merger Sub will merge with and into
the Company, with the Company as the surviving entity of the Denali Merger, and (ii) Longevity Merger Sub will merge with and into Longevity,
with Longevity as the surviving company of the Longevity Merger. Following the Mergers, each of Longevity and the Company will be a subsidiary
of New PubCo, and New PubCo will become a publicly traded company. At Closing, New PubCo will change its name to Longevity Biomedical,
Inc., and its common stock is expected to list on the Nasdaq Capital Market under the ticker symbol “LBIO.”
On March 29, 2023, Denali SPAC Holdco, Inc. filed
a Registration Statement on Form S-4 (as may be amended or supplemented from time to time, the “Form S-4” or the “Registration
Statement”) with the SEC, which includes a preliminary proxy statement and a prospectus in connection with the proposed Transactions.
For more information about the Merger Agreement
and the proposed Longevity Business Combination, see our Current Report on Form 8-K/A filed with the SEC on January 26, 2023 and Form
S-4 filed with the SEC on March 29, 2023, as amended by Amendments Nos. 1 and 2 thereto, filed with the SEC on May 31, 2023 and July 13,
2023, respectively. Unless specifically stated, this Quarterly Report on Form 10-Q does not give effect to the proposed Transactions and
does not contain the risks associated with the proposed transactions. Such risks and effects relating to the proposed transactions are
included in the Amendment No. 2 to Form S-4 filed with the SEC on July 13, 2023, relating to our proposed business combination with Longevity.
On April 11, 2023, the parties to the Merger Agreement
and the Sponsor entered into an Amendment to and Consent under the Merger Agreement (the “Amendment”). The Amendment provides
for the consent from the Company and the Seller Representative to the execution and issuance of the Convertible Promissory Note (as defined
below) by the Company and amends the Merger Agreement to provide that the repayment of such Convertible Promissory Note by the Company
at the closing of the business combination will not be given effect when calculating the Minimum Cash Amount (as defined in the Merger
Agreement) for purposes of the minimum cash closing condition.
On April 11, 2023, the Company issued a convertible
promissory note (the “Convertible Promissory Note”) in the total principal amount of up to $825,000 to the Sponsor. The Convertible
Promissory Note was issued with an initial principal balance of $412,500, with the remaining $412,500 drawable at the Company’s
request prior to the maturity of the Convertible Promissory Note. The Convertible Promissory Note bears an interest equivalent to the
lowest short-term Applicable Federal Rate, and matures upon the earlier of (i) the closing of the Company’s initial business combination
and (ii) the date of the liquidation of the Company. At the option of the Sponsor, upon consummation of a business combination, the Convertible
Promissory Note may be converted in whole or in part into additional Class A ordinary shares of the Company, at a conversion price of
$10 per ordinary share (the “Conversion Shares”). The terms of the Conversion Shares will be identical to those of the private
placement shares issuable upon conversion of the Private Placement Units that were issued to the Sponsor in connection with the IPO (the
“Private Placement Shares”). In the event that we do not consummate a business combination, the Convertible Promissory Note
will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven.
On April 12, 2023, the Company issued a
press release announcing that it deposited $825,000 into the Trust Account, 50% of this amount being a loan from the
Sponsor in the form of a convertible promissory note and other 50% amount was transferred directly from the remaining cash
on hand balance at that time, in order to extend the period of time it has to consummate a business combination by an additional three
months, from the then current deadline of April 11, 2023 to July 11, 2023.
On July 11, 2023, the Company issued a convertible
promissory note in the total principal amount of $825,000 to FutureTech Capital LLC, a Delaware limited liability company (“FutureTech”)
(the “FutureTech Convertible Promissory Note”). The FutureTech Convertible Promissory Note bears an interest equivalent to
the lowest short-term Applicable Federal Rate and matures upon the earlier of (i) the closing of the Company’s initial business
combination and (ii) the date of the liquidation of the Company. At the option of FutureTech, upon consummation of a business combination,
the FutureTech Convertible Promissory Note may be converted in whole or in part into Conversion Shares. The terms of the Conversion Shares
will be identical to those of the Private Placement Shares. In the event that the Company does not consummate a business combination,
the FutureTech Convertible Promissory Note will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated
or otherwise forgiven.
On July 13, 2023, the Company issued a press
release announcing that an aggregate of $825,000 had been deposited into the Company’s Trust Account, this amount being a loan from the FutureTech Convertible Promissory
Notes issued on July 11, 2023, in order to extend the period of time it has to consummate
a business combination by an additional three months, from the then current deadline of July 11, 2023 to October 11, 2023 (the
“Extension”).
On July 18, 2023, the Sponsor lent another $80,000
to the Company, resulting in the principal amount of the Convertible Promissory Note being increased to $492,500 and the available borrowing
capacity being reduced to $332,500.
Results of Operations
We have neither engaged in any operations nor
generated any operating revenues to date. Our only activities from January 5, 2022 (inception) through June 30, 2023, were organizational
activities, those necessary to prepare for and complete the IPO, and, subsequent to the IPO, identifying a target company for a business
combination and activities in connection with the proposed Longevity Business Combination. We do not expect to generate any operating
revenues until after the completion of our initial business combination. We are generating non-operating income in the form of interest
income on marketable securities held after the IPO. We have incurred and will continue to incur increased expenses as a result of being
a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection
with searching for, and completing, a business combination.
For the three months ended June 30, 2023, we
had a net income of $457,709 which primarily consists of income earned on investment held in the Trust Account of $1,025,859 being
partially offset by formation and operating expenses of $563,701 and interest expense – related party of $4,449.
For the six months ended June 30, 2023, we had
a net loss of $551,393 which primarily consists of formation and operating expenses of $2,485,449 and interest expense – related party of $4,449 being partially offset by income earned on investment
held in the Trust Account of $1,938,505.
For the three months ended June 30, 2022, we
had a net loss of $30,847 which primarily consisted of formation and operating expenses of $145,678 being partially offset by
income earned on investment held in the Trust Account of $114,831.
For the period from January 5, 2022
(inception) through June 30, 2022, we had a net loss of $42,190, which consisted of formation and operating costs of $157,021 being
partially offset by income earned on investment held in the Trust Account of $114,831.
Cash Flows from Operating Activities
For
the six months ended June 30, 2023, net cash used in operating activities was $398,123, primarily due to a net loss of $551,393
for the period and the changes in current assets and liabilities of $2,091,775, primarily due to prepaid expenses of $42,764 and accounts
payable, accrued expenses of $2,044,562 and accrued interest expense – related party of $4,449. In addition, net cash used in operating
activities includes adjustments to reconcile net loss from income on the Trust Account of $1,938,505.
For the period from January 5, 2022 (inception) through June 30, 2022,
net cash used in operations was $218,645 primarily due to a net loss of $42,190 for the period and the changes in current assets and liabilities
of $72,967, which consisted of prepaid expenses of $153,770 and accounts payable and accrued expenses of $80,803. In addition, net cash
used in operating activities includes adjustments to reconcile net loss from formation costs paid by related party of $11,343 and income
on Trust Account of $114,831.
Cash Flows from Investing Activities
For the six months ended June 30, 2023, net cash
used in investing activities was $825,000 primarily due to investment held in Trust Account of $825,000 To extend the period of time the Company has to consummate its initial business combination by an additional
three months, from the then current deadline of April 11, 2023 to July 11, 2023.
For the period from January 5, 2022
(inception) through June 30, 2022, net cash used in investing activities was $84,150,000 primarily due to investment held in Trust
Account of $84,150,000 following the consummation of the IPO on April 11, 2022.
Cash Flows from Financing Activities
For the six months ended June 30, 2023, net cash
provided by financing activities was $412,500 primarily due to proceeds from issuance of promissory note to related party of $412,500.
For the period from January 5, 2022
(inception) through June 30, 2022, net cash provided by financing activities was $85,477,342 primarily due to proceeds from issuance
of promissory note to related party of $80,000, proceeds from related party of $25,000 and proceeds from issuance of Private
Placement Units of $5,100,000, proceeds from issuance of Public Units through public offering of $82,500,000, partially offset by
payment of promissory note to related party of $80,000, payment to related party of $160,020, payment of offering costs of $337,638
and payment of underwriter’s discount of $1,650,000.
Liquidity and Capital Resources
Our liquidity needs prior to the consummation
of the IPO were satisfied through a payment from the Sponsor and the loan under an unsecured promissory note from the Sponsor of up to
$400,000 (the “Promissory Note”).
On April 11, 2022, we consummated the IPO of 8,250,000
Units, inclusive of 750,000 Units issued pursuant to the partial exercise by the underwriters of their over-allotment option. The Units
were sold at a price of $10.00 per Unit, generating gross proceeds of $82,500,000. Simultaneously with the closing of the IPO, we consummated
the sale of 510,000 Private Placement Units, inclusive of 30,000 Private Placement Units sold to the Sponsor pursuant to the underwriters’
partial exercise of their over-allotment option. Each whole Private Placement Unit consists of one Class A ordinary share and one warrant,
each whole warrant entitling the holder thereof to purchase one Class A ordinary share at an exercise price of $11.50 per share. The Private
Placement Units were sold at a price of $10.00 per Private Placement Unit, generating gross proceeds of $5,100,000.
Following the closing of the IPO and sale of the
Private Placement Units on April 11, 2022, a total of $84,150,000 was placed in the Trust Account, and we had $1,515,795 of cash held
outside of the Trust Account, after payment of costs related to the IPO, and available for working capital purposes. In connection with
the IPO, we incurred $5,105,315 in transaction costs, consisting of $1,650,000 of underwriting fees, $2,887,500 of deferred underwriting
fees and $567,815 of other offering costs. As of June 30, 2023, we had investment held in the Trust Account of $88,135,105. We intend
to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account
(less income taxes payable), to complete our business combination. To the extent that our share capital or debt is used, in whole or in
part, as consideration to complete a business combination, the remaining proceeds held in the Trust Account will be used as working capital
to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.
As of June 30, 2023, we had cash of $9,125 outside
of the Trust Account. If we do not complete the Longevity Business Combination, we intend to use the funds held outside the Trust Account
primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from
the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents
and material agreements of prospective target businesses, and structure, negotiate and complete a business combination.
On January 25, 2023, we entered into the Merger
Agreement, by and among Longevity, New PubCo, Denali Merger Sub, Longevity Merger Sub, and the Seller Representative.
On March 29, 2023, Denali SPAC HoldCo, Inc. filed
a Form S-4 with the SEC to register shares of its common stock that will be issued in connection with the business combination contemplated
by the Merger Agreement.
On May 31, 2023, Denali SPAC HoldCo, Inc. filed
an amendment to Form S-4 with the SEC to register shares of its common stock that will be issued in connection with the business combination
contemplated by the Merger Agreement.
On July 13, 2023, Denali SPAC HoldCo, Inc. filed
another amendment to Form S-4 with the SEC to register shares of its common stock that will be issued in connection with the business
combination contemplated by the Merger Agreement.
As
of June 30, 2023, we had a working capital deficit of $3,698,702. In order to fund working capital deficiencies or finance transaction
costs in connection with a business combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors
may, but are not obligated to, loan us funds as may be required (the “Working Capital Loans”). If we complete the initial
business combination, we would repay such loaned amounts, or at the lender’s discretion, up to $1.5 million of such Working Capital
Loans may be convertible into units of the post business combination entity at a price of $10.00 per unit. The units would be identical
to the Private Placement Units. In the event that the initial business combination does not close, we may use a portion of the working
capital held outside of the Trust Account to repay such loaned amounts, but no proceeds from the Trust Account would be used for such
repayment. Up to $1,500,000 of such loans may be convertible into units of the post-business combination entity, at a price of $10.00
per unit at the option of the lender. On April 11, 2023, we issued the Convertible Promissory Note in the total principal amount of up
to $825,000 to the Sponsor. The Convertible Promissory Note bears an interest accruing on the unpaid and outstanding total principal
amount at the lowest short-term Applicable Federal Rate as in effect on the date thereof and is payable in arrears on the maturity date.
Interest will be calculated on the basis of a 365-day year and the actual number of days elapsed, to the extent permitted by applicable
law. The Convertible Promissory Note was issued with an initial principal balance of $412,500, with the remaining $412,500 drawable at
the Company’s request prior to the maturity of the Convertible Promissory Note. As of June 30, 2023, there was an amount of $412,500
outstanding under Working Capital Loans in the form of the Convertible Promissory Note. Further, an amount of $4,449 with interest at
4.86% on amount borrowed from the Sponsor for the Extension was recognized as accrued interest expense – related party as of June
30, 2023 and interest expense – related party under other (income)/expenses for the three and six months ended June 30, 2023 in
unaudited condensed consolidated statements of operations. On July 11, 2023, the Company issued a FutureTech Convertible Promissory Note
in the total principal amount of $825,000 to FutureTech and 100% of such amount has been utilized to fund the required payment in order
to extend the period of time to consummate a business combination. On July 18, 2023, the Sponsor lent another $80,000 to the Company,
resulting in the principal amount of the Convertible Promissory Note being increased to $492,500 and the available borrowing capacity being reduced to $332,500.
Based on the foregoing, management believes that
we will not have sufficient working capital and borrowing capacity to meet our needs through the consummation of the initial business
combination. If we are unable to raise additional capital, we may be required to take additional measures to conserve liquidity, which
could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing
overhead expenses. We cannot provide any assurance that new financing will be available to us on commercially acceptable terms, if at
all.
In accordance with Accounting Standards
Codification (“ASC”) Subtopic 205-40, “Presentation of Financial Statements – Going Concern”, the
Company has evaluated that there are certain conditions and events, considered in the aggregate, that raise substantial doubt about
the Company’s ability to continue as a going concern through October 11, 2023 (refer to Note 9 in the unaudited condensed
financial statements), the date that the Company will be required to cease all operations, except for the purpose of winding up, if
a business combination is not consummated. These consolidated financial statements do not include any adjustments relating to the
recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to
continue as a going concern.
If our estimate of the costs of identifying a
target business, undertaking in-depth due diligence and negotiating a business combination are less than the actual amount necessary to
do so, we may have insufficient funds available to operate our business prior to our initial business combination. Moreover, we may need
to obtain additional financing either to complete our business combination or because we become obligated to redeem a significant number
of our public shares upon completion of our business combination, in which case we may issue additional securities or incur debt in connection
with such business combination.
Off-Balance Sheet Arrangements
We have no obligations, assets or liabilities,
which would be considered off-balance sheet arrangements as of June 30, 2023 and December 31, 2022. We do not participate in transactions
that create relationships with entities or financial partnerships, often referred to as variable interest entities, which would have been
established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements,
established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.
Other Contractual Obligations
Registration Rights
The holders of our founder shares, Private Placement
Shares and Private Placement Warrants, including any of those issued upon conversion of any Working Capital Loans (and any Private Placement
Shares issuable upon the exercise of the Private Placement Warrants that may be issued upon conversion of any Working Capital Loans) will
be entitled to registration rights pursuant to a registration and shareholder rights agreement signed on April 6, 2022. The holders of
these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition,
the holders have certain “piggy-back” registration rights with respect to registration statements filed after the completion
of our initial business combination and rights to require us to register for resale such securities pursuant to Rule 415 under the Securities
Act. We will bear the costs and expenses of filing any such registration statements.
Underwriting Agreement
The underwriters received a cash underwriting
discount of $0.20 per Unit, or $1,650,000 in the aggregate, paid upon the closing of the IPO. In addition, the underwriters will be entitled
to a deferred fee of $0.35 per Unit, or $2,887,500 in the aggregate. The deferred fee will become payable to the underwriters from the
amounts held in the Trust Account solely in the event that we complete a business combination, subject to the terms of the underwriting
agreement.
Critical Accounting Policies
The preparation of consolidated financial
statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated
financial statements, and income and expenses during the periods reported. Actual results could materially differ from those
estimates. Please refer to the Critical Accounting Policies section of the Company’s Annual Report on Form 10-K filed
with the SEC on March 17, 2023. There have been no changes to those policies, except as follows:
Convertible Debt
The Company issues debt that may have conversion
features.
Convertible debt – derivative treatment
– When the Company issues debt with a conversion feature, we must first assess whether the embedded equity-linked component is clearly and closely related to its host instruments. If a component is clearly
and closely related to its host instruments, then we have to assess whether the conversion feature meets the requirements
to be treated as a derivative, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional
amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes
the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion
can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated
from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity.
The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in shareholders’ equity in its
statement of financial position.
If the conversion feature within convertible debt
meets the requirements to be treated as a derivative, we estimate the fair value of the embedded derivative using the Black Scholes method
upon the date of issuance. If the fair value of the embedded derivative is higher than the face value of the convertible debt, the excess
is immediately recognized as interest expense. The derivative shall be recorded at fair value as liability and the carrying value assigned
to the host contract represents the difference between the previous carrying amount of the hybrid instrument and the fair value of the
derivative; therefore, there is no gain or loss from the initial recognition and measurement of an embedded derivative that is accounted
for separately from its host contract.
Convertible debt – beneficial conversion
feature – If the conversion feature is not treated as a derivative, we assess whether it is a beneficial conversion feature
(“BCF”). A BCF exists if the conversion price of the convertible debt instrument is less than the share price on the commitment
date. The value of a BCF is equal to the intrinsic value of the feature, the difference between the conversion price and the class of
shares into which it is convertible and is recorded as additional paid in capital and as a debt discount in the condensed consolidated
balance sheets. The Company amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the
condensed consolidated statements of operations. If the debt is retired early, the associated debt discount is then recognized immediately
as amortization of debt discount expense in the condensed consolidated statements of operations.
Convertible debt – contingent beneficial
conversion feature – When assessing the convertible debt for BCF, we also assess whether the conversion feature meets the requirements
to be treated as contingent beneficial conversion feature (“Contingent BCF”), as follows: a) the instrument becomes convertible
only upon the occurrence of a future event outside the control of the holder; b) the instrument is convertible from inception but contains
conversion terms that change upon the occurrence of a future event. If the conversion feature is within convertible debt meets the requirement
to be treated as Contingent BCF, it shall not be recognized in the earnings until the contingency is resolved.
If the conversion feature does not qualify for either the derivative
treatment or as a BCF (including Contingent BCF), the convertible debt is treated as traditional debt.
The conversion feature in convertible promissory note issued by the Company on April 11, 2023, does not qualify for either the derivative
treatment or for BCF. These have been treated as Contingent BCF which shall not be recognized in the earnings until the contingency is
resolved. These convertible promissory notes are presented as traditional debt as of June 30, 2023 in unaudited condensed consolidated
balance sheets.
Recent Accounting Pronouncements
In August 2020, the FASB issued Accounting
Standards Update (“ASU”) No. 2020-06, “Debt — Debt with Conversion and Other Options (Subtopic 470-20) and
Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and
Contracts in an Entity’s Own Equity (“ASU 2020-06”)”, which simplifies accounting for convertible
instruments by removing major separation models required under current U.S. GAAP. The ASU also removes certain settlement conditions
that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings
per share calculation in certain areas. ASU 2020-06 is effective January 1, 2024, and should be applied on a full or modified
retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if
any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.
Management does not believe that any other
recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on our consolidated
financial statements.
Item 3. Quantitative and Qualitative Disclosures
About Market Risk
The net proceeds of our IPO and the Private Placement
held in the Trust Account are invested in U.S. government securities with a maturity of 185 days or less or in money market funds meeting
certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations.
Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are controls
and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the
Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure
controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed
in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive
Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
As required by Rules 13a-15f and 15d-15 under
the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design
and operation of our disclosure controls and procedures as of June 30, 2023. Based upon their evaluation, our Chief Executive Officer
and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under
the Exchange Act) were effective.
Changes in Internal Control over Financial
Reporting
During the quarter ended June 30, 2023, there has been no change
in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal
control over financial reporting.
Part
II. OTHER INFORMATION
Item
1. LEGAL PROCEEDINGS.
None.
Item 1A. Risk Factors.
Factors that could cause our actual results to
differ materially from those in this Quarterly Report are any of the risks contained in our registration statement on Form S-1 (File No.
263123) filed in connection with our IPO, our Annual Report on Form 10-K for the annual period ended December 31, 2022, and the Registration
Statement on Form S-4 by Denali SPAC Holdco, Inc., relating to our proposed business combination with Longevity (File No. 333-270917),
as filed with the SEC on March 17, 2023 and March 29, 2023, respectively.
As of the date of this Quarterly Report, there
have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the annual period ended December 31,
2022, as filed with the SEC on March 17, 2023, and the Registration Statement on Form S-4 by Denali SPAC Holdco, Inc., as filed with the
SEC on March 29, 2023, as amended by Amendments Nos. 1 and 2 thereto, filed with the SEC on May 31, 2023 and July 13, 2023, respectively,
relating to our proposed business combination with Longevity (File No. 333-270917). However, we may disclose changes to such factors or
disclose additional factors from time to time in our future filings with the SEC.
Item
2. UNREGISTERED SALES OF EQUITY SECURITIES AND
USE OF PROCEEDS.
None.
Item
3. DEFAULTS UPON SENIOR SECURITIES.
None.
Item
4. MINE SAFETY DISCLOSURES.
Not applicable.
Item
5. OTHER INFORMATION.
None.
Item
6. EXHIBITS.
The following exhibits are filed as part of,
or incorporated by reference into, this Quarterly Report on Form 10-Q.
* |
Incorporated herein by reference as indicated. |
Part
III.
SIGNATURES
Pursuant to the requirements of Securities Exchange
Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: August 15, 2023 |
DENALI CAPITAL ACQUISITION CORP. |
|
|
|
|
By: |
/s/ Lei Huang |
|
|
Chief Executive Officer |
|
|
(Principal Executive Officer) |
|
|
|
|
By: |
/s/ You “Patrick” Sun |
|
|
Chief Financial Officer |
|
|
(Principal Financial and Accounting Officer) |
31
3775424
7343407
8250000
8250000
0.03
0.10
0.55
1.41
1886992
2495852
2572500
2572500
0.13
0.31
1.64
2.85
0.03
0.10
0.13
0.31
0.55
1.41
1.64
2.85
false
--12-31
Q2
0001913577
0001913577
2023-01-01
2023-06-30
0001913577
deca:UnitsEachConsistingOfOneClassAOrdinaryShareAndOneRedeemableWarrantMember
2023-01-01
2023-06-30
0001913577
deca:ClassAOrdinarySharesParValue00001PerShareMember
2023-01-01
2023-06-30
0001913577
deca:WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember
2023-01-01
2023-06-30
0001913577
us-gaap:CommonClassAMember
2023-08-15
0001913577
us-gaap:CommonClassBMember
2023-08-15
0001913577
2023-06-30
0001913577
2022-12-31
0001913577
us-gaap:CommonClassAMember
2023-06-30
0001913577
us-gaap:CommonClassAMember
2022-12-31
0001913577
us-gaap:CommonClassBMember
2023-06-30
0001913577
us-gaap:CommonClassBMember
2022-12-31
0001913577
2023-04-01
2023-06-30
0001913577
2022-04-01
2022-06-30
0001913577
2022-01-05
2022-06-30
0001913577
deca:RedeemableCommonStockMember
2023-04-01
2023-06-30
0001913577
deca:RedeemableCommonStockMember
2022-04-01
2022-06-30
0001913577
deca:RedeemableCommonStockMember
2023-01-01
2023-06-30
0001913577
deca:RedeemableCommonStockMember
2022-01-05
2022-06-30
0001913577
deca:NonRedeemableCommonStockMember
2023-04-01
2023-06-30
0001913577
deca:NonRedeemableCommonStockMember
2022-04-01
2022-06-30
0001913577
deca:NonRedeemableCommonStockMember
2023-01-01
2023-06-30
0001913577
deca:NonRedeemableCommonStockMember
2022-01-05
2022-06-30
0001913577
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-12-31
0001913577
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-12-31
0001913577
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001913577
us-gaap:RetainedEarningsMember
2022-12-31
0001913577
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001913577
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001913577
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001913577
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001913577
2023-01-01
2023-03-31
0001913577
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2023-03-31
0001913577
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-03-31
0001913577
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001913577
us-gaap:RetainedEarningsMember
2023-03-31
0001913577
2023-03-31
0001913577
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001913577
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001913577
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0001913577
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0001913577
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2023-06-30
0001913577
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-06-30
0001913577
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001913577
us-gaap:RetainedEarningsMember
2023-06-30
0001913577
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-01-04
0001913577
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-01-04
0001913577
us-gaap:AdditionalPaidInCapitalMember
2022-01-04
0001913577
us-gaap:RetainedEarningsMember
2022-01-04
0001913577
2022-01-04
0001913577
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-01-05
2022-03-31
0001913577
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-01-05
2022-03-31
0001913577
us-gaap:AdditionalPaidInCapitalMember
2022-01-05
2022-03-31
0001913577
us-gaap:RetainedEarningsMember
2022-01-05
2022-03-31
0001913577
2022-01-05
2022-03-31
0001913577
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-03-31
0001913577
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-03-31
0001913577
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001913577
us-gaap:RetainedEarningsMember
2022-03-31
0001913577
2022-03-31
0001913577
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001913577
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001913577
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0001913577
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0001913577
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-06-30
0001913577
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-06-30
0001913577
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001913577
us-gaap:RetainedEarningsMember
2022-06-30
0001913577
2022-06-30
0001913577
deca:PublicSharesMember
us-gaap:IPOMember
2022-04-11
2022-04-11
0001913577
deca:PublicSharesMember
us-gaap:OverAllotmentOptionMember
2022-04-11
2022-04-11
0001913577
deca:PublicSharesMember
us-gaap:CommonClassAMember
2022-04-11
0001913577
deca:PublicSharesMember
2022-04-11
0001913577
us-gaap:IPOMember
2022-04-11
2022-04-11
0001913577
us-gaap:OverAllotmentOptionMember
2022-04-11
2022-04-11
0001913577
deca:SponsorMember
2022-04-11
0001913577
deca:SponsorMember
us-gaap:PrivatePlacementMember
2022-04-11
2022-04-11
0001913577
2022-04-11
0001913577
us-gaap:IPOMember
2022-04-11
0001913577
2022-04-11
2022-04-11
0001913577
2023-04-12
0001913577
2023-04-12
2023-04-12
0001913577
deca:PostBusinessCombinationCompanyMember
2023-06-30
0001913577
us-gaap:CommonClassBMember
2022-11-08
2022-11-08
0001913577
deca:SponsorMembershipUnitsMember
2022-11-08
2022-11-08
0001913577
deca:SponsorMembershipInterestPurchaseAgreementMember
2022-11-08
2022-11-08
0001913577
deca:SponsorMembershipInterestPurchaseAgreementMember
2023-01-01
2023-06-30
0001913577
deca:ConvertiblePromissoryNoteMember
deca:SponsorMember
2023-04-11
0001913577
deca:ConvertiblePromissoryNoteMember
2023-04-11
0001913577
deca:SponsorMember
2023-04-12
0001913577
2023-04-01
2023-04-12
0001913577
deca:SponsorMember
2023-04-01
2023-04-12
0001913577
2023-07-13
0001913577
deca:ConvertiblePromissoryNoteMember
deca:SponsorMember
us-gaap:SubsequentEventMember
2023-07-13
2023-07-13
0001913577
deca:SponsorMember
2023-07-18
2023-07-18
0001913577
deca:ConvertiblePromissoryNoteMember
2023-07-18
0001913577
us-gaap:SubsequentEventMember
2023-07-18
0001913577
deca:SponsorMember
2023-01-01
2023-06-30
0001913577
deca:WorkingCapitalLoanMember
deca:SponsorMember
2023-01-01
2023-06-30
0001913577
deca:SponsorMember
2023-06-30
0001913577
deca:WorkingCapitalLoanMember
deca:SponsorMember
2023-06-30
0001913577
deca:ConvertiblePromissoryNoteMember
deca:SponsorMember
2023-06-30
0001913577
deca:WorkingCapitalLoanMember
2023-06-30
0001913577
2023-07-18
2023-07-18
0001913577
us-gaap:SubsequentEventMember
2023-07-11
0001913577
2023-07-11
2023-07-11
0001913577
deca:SponsorMember
2023-07-18
0001913577
deca:PublicSharesMember
2023-06-30
0001913577
deca:PublicWarrantsMember
2023-06-30
0001913577
deca:PublicWarrantsMember
2023-01-01
2023-06-30
0001913577
deca:PrivatePlacementWarrantsMember
2023-01-01
2023-06-30
0001913577
deca:FounderSharesMember
us-gaap:OverAllotmentOptionMember
2022-04-01
2022-06-30
0001913577
us-gaap:CommonClassAMember
2022-01-01
2022-12-31
0001913577
us-gaap:CommonClassAMember
2023-01-01
2023-03-31
0001913577
us-gaap:CommonClassAMember
2023-04-01
2023-06-30
0001913577
deca:RedeemableSharesMember
2023-04-01
2023-06-30
0001913577
deca:NonRedeemableSharesMember
2023-04-01
2023-06-30
0001913577
deca:RedeemableSharesMember
2023-01-01
2023-06-30
0001913577
deca:NonRedeemableSharesMember
2023-01-01
2023-06-30
0001913577
deca:RedeemableSharesMember
2022-04-01
2022-06-30
0001913577
deca:NonRedeemableSharesMember
2022-04-01
2022-06-30
0001913577
deca:RedeemableSharesMember
2022-01-05
2022-06-30
0001913577
deca:NonRedeemableSharesMember
2022-01-05
2022-06-30
0001913577
srt:MinimumMember
2023-01-01
2023-06-30
0001913577
srt:MaximumMember
2023-01-01
2023-06-30
0001913577
us-gaap:PrivatePlacementMember
2023-01-01
2023-06-30
0001913577
us-gaap:OverAllotmentOptionMember
2023-01-01
2023-06-30
0001913577
us-gaap:PrivatePlacementMember
2023-06-30
0001913577
deca:FounderSharesMember
deca:SponsorMember
2022-02-01
2022-02-03
0001913577
deca:FounderSharesMember
deca:SponsorMember
2022-02-03
0001913577
srt:ChiefFinancialOfficerMember
deca:SponsorMember
2022-03-01
2022-03-31
0001913577
srt:DirectorMember
deca:PerformanceBasedRestrictedStockAwardsMember
deca:SponsorMember
2022-03-01
2022-03-31
0001913577
us-gaap:OverAllotmentOptionMember
2022-05-23
2022-05-23
0001913577
deca:UnderwritingAgreementMember
us-gaap:OverAllotmentOptionMember
2022-05-23
2022-05-23
0001913577
deca:SharesOutstandingAfterInterseTransferOfSharesMember
deca:SponsorMember
2022-05-23
0001913577
deca:FounderSharesMember
2023-01-01
2023-06-30
0001913577
srt:DirectorMember
deca:PerformanceBasedRestrictedStockAwardsMember
deca:SponsorMember
2023-01-01
2023-06-30
0001913577
2022-02-01
2022-02-03
0001913577
deca:PromissoryNoteMember
deca:SponsorMember
2022-04-11
0001913577
deca:SponsorMember
2023-01-05
2023-03-31
0001913577
2022-04-12
2022-04-12
0001913577
2022-04-14
2022-04-14
0001913577
2022-07-19
2022-07-19
0001913577
us-gaap:ConvertibleNotesPayableMember
2023-04-11
0001913577
2023-04-11
0001913577
deca:SponsorMember
2023-06-30
0001913577
2023-07-01
2023-07-18
0001913577
deca:SponsorMember
2023-04-11
0001913577
us-gaap:CommonClassBMember
us-gaap:OverAllotmentOptionMember
2022-05-23
0001913577
us-gaap:WarrantMember
2023-06-30
0001913577
us-gaap:CommonClassAMember
us-gaap:WarrantMember
2023-06-30
0001913577
us-gaap:CommonClassAMember
us-gaap:WarrantMember
2023-01-01
2023-06-30
0001913577
us-gaap:WarrantMember
2023-01-01
2023-06-30
0001913577
us-gaap:FairValueInputsLevel1Member
2023-06-30
0001913577
us-gaap:FairValueInputsLevel2Member
2023-06-30
0001913577
us-gaap:FairValueInputsLevel3Member
2023-06-30
0001913577
us-gaap:FairValueInputsLevel1Member
2022-12-31
0001913577
us-gaap:FairValueInputsLevel2Member
2022-12-31
0001913577
us-gaap:FairValueInputsLevel3Member
2022-12-31
0001913577
us-gaap:SubsequentEventMember
2023-07-01
2023-07-11
0001913577
us-gaap:SubsequentEventMember
2023-07-01
2023-07-13
0001913577
us-gaap:SubsequentEventMember
deca:SponsorMember
2023-07-01
2023-07-18
0001913577
us-gaap:SubsequentEventMember
2023-07-01
2023-07-18
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
In connection with the Quarterly Report of Denali Capital Acquisition
Corp. (the “Company”) on Form 10-Q for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission
on the date hereof (the “Report”), I, Lei Huang, Chief Executive Officer and Director of the Company, certify, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
In connection with the Quarterly Report of Denali Capital Acquisition
Corp. (the “Company”) on Form 10-Q for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission
on the date hereof (the “Report”), I, You (“Patrick”) Sun, Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: